AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02247011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biochemical markers analysis
Description: Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
Study NCT01207076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90Y-AHN-12
Description: The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy.
Study NCT02965742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratos
Description: A machine made by DMS group.
Study NCT02965742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hologic QDR 4500A
Description: A machine made by Hologic inc.
Study NCT02965742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hologic HORIZON A
Description: A machine made by Hologic inc.
Study NCT01532284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polar Body Biopsy
Description: PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
Study NCT03170115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
Study NCT03170115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
Study NCT03684603 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: melody during motor training and slow wave sleep
Description: sequence of tones which are presented to the patient using earphones
Study NCT03684603 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: melody only during motor training
Description: sequence of tones which are presented to the patient using earphones
Study NCT00753103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Daily oral 1mg/kg tapered over 12 months
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Daily oral 1mg/kg tapered over 12 months
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
Study NCT00753103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchange
Description: Additional therapy for patients with severe vasculitis (creatinine > 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 500 mg intravenous infusion daily for three days at lead physicians discretion.
Study NCT00753103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 500 mg intravenous infusion daily for three days at lead physicians discretion.
Study NCT02091752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
Study NCT03938337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 Not Previously Treated
Description: Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
Study NCT03938337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 Treated Previously
Description: Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
Study NCT00729209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule
Study NCT00729209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study NCT04777383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Iontophoretic administration of 5 different concentrations of acetylcholine
Study NCT02731677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
Study NCT02609841 — intervention group
Intervention type: DEVICE
Intervention: Cardiac rhythm remote monitoring system
Description: Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
Study NCT03227653 — intervention group
Intervention type: DRUG
Intervention: Efavirenz
Description: Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
Study NCT03227653 — intervention group
Intervention type: DRUG
Intervention: Nevirapine
Description: Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
Study NCT03227653 — intervention group
Intervention type: DRUG
Intervention: Lopinavir-Ritonavir Drug Combination
Description: Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
Study NCT04486430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL
Description: 1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
Study NCT04486430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL
Description: 1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
Study NCT04486430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL
Description: 1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
Study NCT04486430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
Study NCT01944098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT01944098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03702348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
Study NCT01639339 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Placebo plus standard therapy
Study NCT01639339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg plus standard therapy
Description: Belimumab 10 mg/kg plus standard therapy
Study NCT01639339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy
Study NCT01639339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy
Study NCT01738607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Study NCT01738607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Gum acacia dietary fiber
Study NCT01738607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose
Description: dietary fiber
Study NCT01738607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04777383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Iontophoretic administration of 5 different concentrations of norepinephrine
Study NCT04777383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Iontophoretic administration of 5 different concentrations of phenylephrine
Study NCT04777383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Iontophoretic administration of 5 different concentrations of atropine
Study NCT04777383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Iontophoretic administration of 5 different concentrations of neostigmine
Study NCT04777383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile water
Description: Iontophoretic administration of sterile water
Study NCT04029090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
Study NCT04029090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
Study NCT04029090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
Study NCT03658343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: T2* Imaging
Description: T2\* imaging sequences for MRI
Study NCT01953198 — intervention group
Intervention type: OTHER
Intervention: Hypobaric hypoxia
Description: Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
Study NCT03048565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
Study NCT01661777 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nasal steroid
Study NCT01871571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01661777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myringotomy tube placement
Study NCT01661777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic
Study NCT00000105 — intervention group
Intervention type: BIOLOGICAL
Intervention: Intracel KLH Vaccine
Description: Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
Study NCT00000105 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biosyn KLH
Description: Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
Study NCT01661777 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antihistamine
Study NCT01661777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low salt diet
Study NCT01605604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: buddhist mind fullness
Description: there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
Study NCT02342457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Child suspected of Hirschsprung disease
Description: Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
Study NCT03070223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
Study NCT03070223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
Study NCT03926572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A biobank will be created from blood samples taken at admission, days 3 and days 7
Description: A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
Study NCT03635424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic TAVR Systems
Description: Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
Study NCT00767663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dipyridamole
Description: dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
Study NCT00767663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice daily, minimal three days pretreatment
Study NCT01424748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tahitian Noni Juice
Description: noni fruit juice
Study NCT00000105 — intervention group
Intervention type: DRUG
Intervention: Montanide ISA51
Description: Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
Study NCT00000105 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tetanus toxoid
Description: Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
Study NCT01424748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo juice
Study NCT01753869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airways clearance and Hypertonic saline inhalation
Study NCT05348070 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy/Laparotomy
Description: All patients included in the study were operated patients.
Study NCT03011814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03011814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03011814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01781468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil 150 mg
Description: given orally
Study NCT01781468 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: given orally
Study NCT01781468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil 250 mg
Description: given orally
Study NCT02324569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 tablets
Study NCT02324569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets
Study NCT00791245 — intervention group
Intervention type: BIOLOGICAL
Intervention: Particulated Juvenile Cartilage Allograft
Description: Particulated Juvenile Cartilage Allograft
Study NCT02395380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-reactive protein dosage
Study NCT04669782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K (MK7)
Description: MK-7 will be administered at a dose of 375 microg / day
Study NCT04669782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide will be administered as standard of care
Study NCT04669782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be administered as standard of care
Study NCT02852824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130 (spesolimab)
Study NCT02852824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00999336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: 80 mg betrixaban qd for 8 days
Study NCT03541980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
Study NCT03541980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline volume equivalent
Study NCT03745157 — intervention group
Intervention type: DRUG
Intervention: Insulin Degludec/Insulin Aspart
Description: Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
Study NCT00999336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betrixaban
Description: 80 mg betrixaban qd for 8 days
Study NCT06778200 — intervention group
Intervention type: OTHER
Intervention: client interview
Description: using a data collection form clients voluntarily described services provided by practitioner
Study NCT06778200 — intervention group
Intervention type: OTHER
Intervention: practitioner responses
Description: completed reflections after each module completion
Study NCT01352221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST10
Description: 30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
Study NCT03791736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of sandostatine
Description: Intramuscular injection of sandostatin 30 mg 3 days before surgery
Study NCT01012063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose, erythropoietin-β
Description: The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
Study NCT01012063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.